drugset / Trial / NCT07023848
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
Non-randomizedCrossoverOpen-labelDiagnostic
Summary
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibody fragments in diagnosis and screening of HER2-positive cancer patients.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-07-07
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 3.7 mbq/kg | Intravenous |
| Subject | 18F-FDG | Diagnostic / imaging agent | 5.55 mbq/kg | Intravenous |
| Subject | 89Zr-LNCab103 | Diagnostic / imaging agent | 37 mbq | Intravenous |
| Subject | 89Zr-LNCab103 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 89Zr-LNCab104 | Diagnostic / imaging agent | 37 mbq | Intravenous |
| Subject | 89Zr-LNCab104 | Diagnostic / imaging agent | 111 mbq | Intravenous |